GlassScriptPhysician profile
Nadim Geloo
NPI 1467432146
$41,435.19
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $21K · 2021: $1,053 · 2022: $323.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $35,791.61 | 2019-2020 | |
| Abbott Laboratories | $3,833.15 | 2019-2022 | |
| Medtronic, INC. | $723.68 | 2021 | |
| Cardiovascular Systems INC. | $287.09 | 2019-2021 | |
| Biotronik INC. | $163.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $158.60 | 2019-2020 | |
| Abiomed | $144.58 | 2019 | |
| Edwards Lifesciences Corporation | $113.99 | 2019 | |
| Pfizer INC. | $41.10 | 2019-2020 | |
| Amgen INC. | $40.22 | 2019-2021 | |
| Boston Scientific Corporation | $37.35 | 2019 | |
| United Therapeutics Corporation | $21.42 | 2019 | |
| Livanova USA, INC. | $15.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.15 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celonova Biosciences, INC. | $13.28 | 2019 | |
| Amarin Pharma, INC. | $12.38 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadim Geloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.